Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N) - PubMed
4 hours ago
- #PRRT
- #177Lu-DOTATATE
- #neuroendocrine neoplasm
- Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE was studied in Japanese patients with advanced neuroendocrine neoplasms (NENs).
- The study included 422 patients from 33 institutions in Japan, with efficacy analyzed in 383 patients.
- The most common primary tumor sites were pancreas (54.8%) and hindgut (21.1%), with fewer midgut cases (5.0%).
- Tumor grades were G1 (13.3%), G2 (71.2%), G3 (14.6%), and neuroendocrine carcinoma (1.8%).
- Objective response rate (ORR) was 37.6%, with higher rates in pancreatic (45.2%) and hindgut (40.7%) NENs.
- Median progression-free survival (PFS) was 21.4 months (95% CI, 19.7-22.8).
- 75% of patients with hormonal symptoms showed marked improvement.
- Predictors for ORR included pancreas or hindgut primary site, Krenning score of 4, and liver metastasis ≤ 30 mm.
- Predictors for PFS included Ki-67 < 10%, Krenning score of 4, liver tumor burden < 50%, liver tumor size ≤ 30 mm, and combination with somatostatin analogs.
- Grade ≥ 3 adverse events were infrequent, including hematologic (18%) and renal toxicities (< 1%).
- 177Lu-DOTATATE demonstrated favorable efficacy and safety, particularly for pancreatic and hindgut NENs.